Table of Contents

Chapter 1  History of Drug Discovery  1
Chapter 2  Target Identification and Validation  43
Chapter 3  In Vitro and In Vivo Assays  67
Chapter 4  Drug Metabolism and Pharmacokinetics in Drug Discovery  99
Chapter 5  Cardiovascular Drugs  141
Chapter 6  Diabetes Drugs  205
Chapter 7  CNS Drugs  245
Chapter 8  Cancer Drugs  287
Chapter 9  Anti-Inflammatory and Immunomodulatory Drugs  337
Chapter 10  Antibacterial Drugs  389
Chapter 11  Antiviral Drug Discovery  439
Index  517
## Detailed Table of Contents

<table>
<thead>
<tr>
<th>Chapter 1</th>
<th>History of Drug Discovery</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>2.</td>
<td>Antibacterials</td>
<td>1</td>
</tr>
<tr>
<td>2.1</td>
<td>Lister and Carbolic Acid</td>
<td>2</td>
</tr>
<tr>
<td>2.2</td>
<td>Dr. Ehrlich's Magic Bullet</td>
<td>3</td>
</tr>
<tr>
<td>2.3</td>
<td>Domagk and Sulfon Drugs</td>
<td>4</td>
</tr>
<tr>
<td>2.4</td>
<td>Fleming, Florey, Chain, and Penicillin</td>
<td>5</td>
</tr>
<tr>
<td>2.5</td>
<td>Waksman, Schatz, and Streptomycin</td>
<td>6</td>
</tr>
<tr>
<td>2.6</td>
<td>Duggar, Conover, and Tetracyclines</td>
<td>7</td>
</tr>
<tr>
<td>2.7</td>
<td>Quinolones and Zyvox</td>
<td>8</td>
</tr>
<tr>
<td>3.</td>
<td>Cancer Drugs</td>
<td>9</td>
</tr>
<tr>
<td>3.1</td>
<td>The Origin of Cancer</td>
<td>10</td>
</tr>
<tr>
<td>3.2</td>
<td>Chemotherapy</td>
<td>11</td>
</tr>
<tr>
<td>3.3</td>
<td>Hormone Treatment</td>
<td>12</td>
</tr>
<tr>
<td>3.4</td>
<td>Small-Molecule Protein Kinase Inhibitors</td>
<td>13</td>
</tr>
<tr>
<td>4.</td>
<td>Cardiovascular Drugs</td>
<td>14</td>
</tr>
<tr>
<td>4.1</td>
<td>Withering and Digitalis</td>
<td>15</td>
</tr>
<tr>
<td>4.2</td>
<td>Sobrero, Nobel, and Nitroglycerin</td>
<td>16</td>
</tr>
<tr>
<td>4.3</td>
<td>Vogl and Diuretics</td>
<td>17</td>
</tr>
<tr>
<td>4.4</td>
<td>Snake Venom and ACE Inhibitors</td>
<td>18</td>
</tr>
<tr>
<td>4.5</td>
<td>Black and Beta-Blockers</td>
<td>19</td>
</tr>
<tr>
<td>4.6</td>
<td>Renin Inhibitor</td>
<td>20</td>
</tr>
<tr>
<td>4.7</td>
<td>Fleckenstein and Calcium Channel Blockers</td>
<td>21</td>
</tr>
<tr>
<td>4.8</td>
<td>Blood Thinners, from Heparin to Plavix</td>
<td>22</td>
</tr>
<tr>
<td>5.</td>
<td>Cholesterol Drugs</td>
<td>23</td>
</tr>
<tr>
<td>5.1</td>
<td>Early Cholesterol Drugs: Niacin and Fibrates</td>
<td>24</td>
</tr>
<tr>
<td>5.2</td>
<td>Endo, Mevasatin, and Pravachol</td>
<td>25</td>
</tr>
<tr>
<td>5.3</td>
<td>Merck's Mevacor and Zocor</td>
<td>26</td>
</tr>
<tr>
<td>5.4</td>
<td>Lescol, Lipitor, Baycol, and Crestor</td>
<td>27</td>
</tr>
<tr>
<td>5.5</td>
<td>Zetia and Vytorin</td>
<td>28</td>
</tr>
<tr>
<td>6.</td>
<td>CNS Drugs</td>
<td>29</td>
</tr>
<tr>
<td>6.1</td>
<td>Sternbach, Valium, and Minor Tranquilizers</td>
<td>30</td>
</tr>
<tr>
<td>6.2</td>
<td>Antidepressants</td>
<td>31</td>
</tr>
<tr>
<td>6.3</td>
<td>Antipsychotics</td>
<td>32</td>
</tr>
<tr>
<td>6.4</td>
<td>Drugs for Epilepsy and Bipolar Disorder</td>
<td>33</td>
</tr>
<tr>
<td>7.</td>
<td>Anti-Inflammatory Drugs</td>
<td>34</td>
</tr>
<tr>
<td>7.1</td>
<td>Cortisone</td>
<td>35</td>
</tr>
<tr>
<td>7.2</td>
<td>Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)</td>
<td>36</td>
</tr>
<tr>
<td>7.3</td>
<td>Anti-asthmatics</td>
<td>37</td>
</tr>
</tbody>
</table>
Contents

Chapter 2  Target Identification and Validation 43

1  Introduction 43
2  Definition of Drug Targets 43
3  Classification of Currently Utilized Drug Targets 45
4  Receptors as Drug Targets 46
   4.1  G-Protein-Coupled Receptors 46
   4.2  Ligand-Gated Ion Channels 47
   4.3  Receptor Tyrosine Kinases 47
   4.4  Nuclear Receptors 48
5  Enzymes as Drug Targets 48
6  Transporter Proteins as Drug Targets 49
7  Modern Technologies Employed in Target Identification and Validation 49
   7.1  Human Genetics 50
   7.2  Gene Family Mining 52
   7.3  Gene Expression Profiling in Target Discovery 53
   7.4  Proteomics 54
   7.5  Oligonucleotides 56
   7.6  Model Organisms 58
8  Impact of Therapeutic Modalities on the Selection Drug Targets 62
9  Future Directions 63
References 63

Chapter 3  In Vitro and In Vivo Assays 67

1  Introduction 67
2  The Testing Funnel 67
3  In Vitro Assays 71
   3.1  High-throughput Screening as a Source of Lead Matter 71
   3.2  The IC₅₀ as a Measure of Inhibitory Potency 73
   3.3  Solubility 75
   3.4  Nonspecific (Promiscuous) Inhibitors 76
   3.5  Mechanism of Inhibition Studies 78
## Contents

3.6 How to Identify Allosteric Inhibitors 82
3.7 Selectivity 83
3.8 Tight-binding Inhibition 84
3.9 Slow-Binding Inhibition, Reversibility, and Residence Time 86
3.10 Mechanism, Kinetics, and Potency Comparisons 89
3.11 Cell Assays 90
4 In Vivo Assays 92
4.1 Pharmacokinetics and Pharmacodynamics 92
4.2 Animal Models of Disease 95
4.3 Scaling Up 95
5 Outlook 96
References 96

### Chapter 4 Drug Metabolism and Pharmacokinetics in Drug Discovery 99

1 Introduction 99
2 Drug Metabolism 101
2.1 Drug-Metabolizing Enzymes 101
2.2 In Vitro and In Vivo Models to Evaluate Drug Metabolism 105
2.3 Metabolic Stability 107
2.4 Reaction Phenotyping 108
2.5 Drug-Drug Interactions 108
3 Pharmacokinetic Fundamentals 110
3.1 Noncompartmental Analysis of Pharmacokinetic Data 112
3.2 Compartmental Analysis of Pharmacokinetic Data 115
4 Pharmacokinetic Studies in Support of Drug Optimization 116
5 Absorption and Permeability 118
6 Drug Transporters 121
7 Protein Binding 123
7.1 Protein-Binding Theory 123
7.2 Role of \( f_u \) in Clearance and Volume of Distribution 125
7.3 Experimental Techniques 126
7.4 Optimization of \( f_u \) in Drug Discovery 127
8 Pharmacokinetics and Pharmacodynamics 127
8.1 Reversible Direct Effects 128
8.2 Time-Delayed Effects 131
9 Predicting Human Pharmacokinetics 134
9.1 Importance of Dose 135
10 Summary 137
References 137
Chapter 5 Cardiovascular Drugs

1 Introduction 141
2 Early History of Coronary Heart Disease (CHD) 142
3 Lipid-Lowering Agents 143
  3.1 Nicotinic Acid Derivatives 144
  3.2 Bile Acid Sequestrants (BAS) 145
  3.3 Fibric acids 146
  3.4 Probucol 147
  3.5 HMG-CoA Reductase Inhibitors 148
  3.6 Cholesterol Absorption Inhibitors 152
  3.7 Triglyceride-lowering Agents 154
  3.8 HDL-Elevating Agents 154
4 Antihypertensive Agents 157
  4.1 Early Vasodilators 159
  4.2 Autonomic Nervous System (Sympatholytic) Approaches to Hypertension 160
  4.3 Diuretics 167
  4.4 Calcium Channel Blockers 171
  4.5 The Renin-Angiotensin-Aldosterone System (RAAS) 173
  4.6 Endothelin Antagonists 180
5 Antithrombotic Drugs 181
  5.1 Antiplatelet Agents 182
  5.2 Anticoagulant Agents 188
6 Thrombolytic Agents 194
7 Antianginal Agents 195
8 Heart Failure Drugs 195
9 The Future 197
References 197

Chapter 6 Diabetes Drugs

1 Introduction 205
  1.1 Homeostasis of Glucose 205
  1.2 Diabetes 206
2 Current therapies for Type 2 Diabetes 208
  2.1 Biguanides 208
  2.2 Insulin Secretagogues: Sulfonylureas and Glinides 210
  2.3 α-Glucosidase Inhibitors 213
  2.4 PPARγ Agonists: Thiazolidinediones (TZDs) 213
  2.5 Incretin-Based Therapies 216
  2.6. Amylin Analog 219
3 Other Treatments for Type 2 Diabetes 219
  3.1 Bile Acid Sequestrants 220
### Contents

3.2 Orlistat 220
3.3 Bromocriptine 221

4 Novel Mechanisms of Action: Future Treatments for Type 2 Diabetes 221
4.1 Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors 221
4.2 PPARs: Next Generation 224
4.3 Glucokinase Activators 225
4.4 GPR119 Agonists 225
4.5 D-Tagatose 225
4.6 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors 226
4.7 Diacylglycerol Acyltransferase 1 (DGAT-1) Inhibitors 226

5 Current Therapies for Type 1 Diabetes 226
5.1 Insulin 226
5.2 Insulin Analogs 228

6 Future Treatments for Type 1 Diabetes 232
6.1 Developments in Insulin Area 232
6.2 Approaches to Fight β-cell Destruction 233

7 Future Prospects for New Diabetes Drugs 236
References 236

### Chapter 7 CNS Drugs 245

1. Introduction 245

2. Antipsychotic Drugs 246
  2.1 Typical Antipsychotics—The First Generation 247
  2.2 Atypical Antipsychotics—The Second Generation 248
  2.3 Recent Development of Newer Agents 250

3. Antidepressant Drugs 252
  3.1 Monoamine Oxidase Inhibitors (MAOIs) 252
  3.2 Tricyclic Antidepressants (TCAs) 253
  3.3 Selective Serotonin Reuptake Inhibitors (SSRIs) 254
  3.4 Combined Noradrenaline/Serotonin Reuptake Inhibitors (SNRIs) 255
  3.5 Novel Approaches 256

4. Drugs for Epilepsy and Bipolar Disorder 259
  4.1 Older Antiepileptics 259
  4.2 Newer Antiepileptics 261

5. Anxiolytic Drugs 263
  5.1 Benzodiazepines 263
  5.2 Novel Anxiolytics 265

6. Centrally Acting Analgesic Drugs 266
  6.1 Opiates 266
Chapter 8  Cancer Drugs  287
  1  Introduction  287
  2  Historical Perspective of Cancer Drugs  289
  3  Antimetabolites  290
      3.1  Folate Antagonists  291
      3.2  Purine and Pyrimidine Antimetabolites  292
  4  Alkylating Agents  295
  5  Platinum Complexes  298
  6  Plant- and Marine-Based Natural Products  299
  7  Topoisomerase Inhibitors  304
      7.1  Topoisomerase I Inhibitors  305
      7.2  Topoisomerase II Inhibitors  307
  8  Antitumor Antibiotics  309
  9  Tyrosine Kinase Inhibitors (TKIs)  310
      9.1  Monoclonal Antibodies  316
  10  Hormones  318
      10.1  Antiestrogens  318
      10.2  Androgens  319
      10.3  Aromatase Inhibitors  320
      10.4  Gonadotropin-Releasing Hormone Agonists  322
      10.5  Gonadotropin-Releasing Hormone Antagonists  324
  11  Histone Deacetylase (HDAC) Inhibitors  325
  12  Miscellaneous Cancer Drugs  327
  13  Conclusion  329
      References  330

Chapter 9  Anti-Inflammatory and Immunomodulatory Drugs  337
  1  Introduction  337
      1.1  Innate Immune Response  337
      1.2  Adaptive Immune Response  338
2 Arachidonic Acid Cascade 343
  2.1 Cyclooxygenase (COX) Inhibitors 344
  2.2 Cyclooxygenase-2 (COX-2) Inhibitors 345
  2.3 Prostaglandin I₂ (Prostacyclin) 349
  2.4 Prostaglandin E₂ 349
  2.5 Thromboxane A₂ 350
3 Leukotriene Pathway Inhibitors 351
  3.1 5-Lipoxygenase Inhibitors 352
  3.2 Leukotriene Receptor Antagonists 353
4 Antihistamines 355
5 Corticosteroids 357
6 Rheumatoid Arthritis 360
  6.1 Methotrexate 362
  6.2 Sulfasalazine 364
  6.3 Minocycline 365
  6.4 Hydroxychloroquine 365
  6.5 Leflunomide 366
7 Osteoarthritis 367
8 Chronic Inflammatory Arthritis and Gout 368
  8.1 Colchicine 368
  8.2 Uricosuric Agents 369
  8.3 Xanthine Oxidase 369
  8.4 Urate Oxidase 370
9 Multiple Sclerosis 370
  9.1 Natalizumab (Tysabri) 370
  9.2 IFN-Beta 371
  9.3 Mitoxantrone 371
  9.4 Glatiramer Acetate (Copaxone) 371
  9.5 Fingolimod 372
10 Transplantation 372
  10.1 Azathioprine 373
  10.2 Cyclosporine 373
  10.3 Tacrolimus 374
  10.4 Sirolimus (Rapamycin) 375
11 Biological Agents That Suppress Cytokine Production or Signaling 376
  11.1 Etanercept 376
  11.2 Infliximab 376
  11.3 Adalimumab 376
  11.4 Golimumab 377
  11.5 Certolizumab Pegol 377
12 B-Cell Therapy 378
  12.1 Rituximab 378
Chapter 10  Antibacterial Drugs 389
1  Introduction 389
2  The Rise and Decline of Antibiotics 389
3  The Unique Challenges of Antibacterial Drug Discovery 390
  3.1  Lead Matter 391
  3.2  Bacterial Targets 391
  3.3  Resistance 391
  3.4  Efflux and Permeability 392
  3.5  Lack of Diagnostics 392
  3.6  Clinical Trials 392
  3.7  Commercial Landscape 393
4  Antibiotic Classes 393
  4.1  Cell Wall Biosynthesis Inhibitors 393
  4.2  Ribosome Inhibitors 403
  4.3  DNA and RNA Synthesis Inhibitors 413
  4.4  Membrane Inhibitors 418
5  Emerging Strategies to Discover New Antibacterial Drugs 423
  5.1  New Compounds, In or Near the Clinic 423
  5.2  Tools for Discovery 423
  5.3  Screening 426
  5.4  New Targets 426
  5.5  Emerging Strategy 427
6  Conclusions 428
References 428
### Contents

**Chapter 11 Antiviral Drug Discovery**

1. **Introduction**
2. **Human Immunodeficiency Virus-1 Inhibitors**
   2.1 **HIV-1 Entry Inhibitors**
   2.2 **HIV-1 Reverse Transcriptase Inhibitors**
   2.3 **HIV-1 Protease Inhibitors**
   2.4 **HIV-1 Integrase Inhibitors**
3. **Hepatitis B Virus Inhibitors**
4. **Hepatitis C Virus Inhibitors**
   4.1 **HCV NS3 Protease Inhibitors**
   4.2 **HCV NS5B RNA-Dependent RNA Polymerase Inhibitors**
   4.3 **Inhibitors of HCV NS5A**
5. **Inhibitors of Respiratory Viruses**
   —— **Influenza and Respiratory Syncytial Virus**
   5.1 **Influenza Virus**
   5.2 **Respiratory Syncytial Virus (RSV)**
6. **Herpesviridae Inhibitors**
   6.1 **Herpes Simplex Viruses 1 and 2**
   6.2 **Varicella zoster Virus (VZV)**
   6.3 **Human Cytomegalovirus (HCMV) Inhibitors**
   6.4 **Epstein-Barr virus (EBV, Human Herpesvirus 4) Inhibitors**
7. **Epilogue**

**Index**

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>439</td>
</tr>
<tr>
<td>439</td>
</tr>
<tr>
<td>444</td>
</tr>
<tr>
<td>446</td>
</tr>
<tr>
<td>449</td>
</tr>
<tr>
<td>453</td>
</tr>
<tr>
<td>458</td>
</tr>
<tr>
<td>460</td>
</tr>
<tr>
<td>464</td>
</tr>
<tr>
<td>464</td>
</tr>
<tr>
<td>467</td>
</tr>
<tr>
<td>474</td>
</tr>
<tr>
<td>476</td>
</tr>
<tr>
<td>476</td>
</tr>
<tr>
<td>481</td>
</tr>
<tr>
<td>485</td>
</tr>
<tr>
<td>486</td>
</tr>
<tr>
<td>486</td>
</tr>
<tr>
<td>487</td>
</tr>
<tr>
<td>488</td>
</tr>
<tr>
<td>489</td>
</tr>
<tr>
<td>489</td>
</tr>
<tr>
<td>517</td>
</tr>
</tbody>
</table>